Member Info for BeanCounting

Did this happen or what! We will soon go into the 0.3s

This is happening

I bet this will be typical travelled and arrived event, the start of production has been such an anticipated event. Stock will pop in the open and then some investor will take profit and sell it down. Tomorrow its back to reality that the project is hardly break-even at the bottom line with the current spod price.

Revenue estimates from 2027 should be upgraded with 30% and this will continue for 7 year. We should see some decent operating leverage give how OPT cost structure works.

Its a typical pattern. Lanstead who has been very tight with the company over the past year and taking part in all recent placing was selling down its position 6th Dec 2024, from 9.99% to 6.9% when the stock was around 1.25p. They have a good feeling that a placing is coming. Then the company goes on a big ramp path which did get plenty of attraction. Similar to Quadrise and QBT.

Next step is the capital raise. The life cycle of AIM.

https://www.londonstockexchange.com/news-article/IMM/holding-s-in-company/16805104

Onlyking, why do you think Hainan wants to take the shares at 0.45p?

Seen this so many times before:

QED big spike now 50% discounted placing announced last night

QBT big spike from 0.7p to 2.2p and this week 1.15p placing

IMM is just the same management is ramping and then raise.

Bernard is dancing around the elephant in the room

Its an attempt to create interest so they can raise funds.

The company had £2.72m in cash 30 June 2024

They used £1.87m in cash during H1 2024.

Based on the same burn rate in H2, they will end 2024 with £850k in cash and will need to raise in Q1 2025. We are talking couple of months.

HEX doing a road show in London next week and investor call, we all know what that means, placing time.

Based on the last interim report and cash burn it looks like the company will need to raise funds very soon.

It shows that they want to close the deal.

Yeah what happened to MD Anderson? Odd

Hemogenyx Pharmaceuticals Opens First Clinical Site for HG-CT-1 Phase I Trial

Patient Recruitment Begins for CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia in Adults

Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce the opening of the first clinical site for its lead asset, HG-CT-1, targeting relapsed/refractory (R/R) acute myeloid leukemia (AML) in adults. Recruitment of patients for the trials has begun.

This Phase I trial is designed as a dose-escalation study to evaluate the safety profile of HG-CT-1 in adult patients with R/R AML. Key secondary objectives include assessing the therapy's impact on the following clinical outcomes:

· Efficacy of HG-CT-1 based on AML-specific response criteria

· Overall survival (OS) rates among participating subjects

· Progression-free survival (PFS) in evaluable subjects

· Duration of response (DoR) in those who achieve clinical responses.

These objectives are pivotal for assessing the overall clinical impact of HG-CT-1 on patients with R/R AML, a population with few remaining therapeutic options. The commencement of this trial represents a major milestone for Hemogenyx Pharmaceuticals, enabling the Company to advance this promising therapy into clinical testing at one of the world's most prestigious cancer research institutions.

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:

" The opening of our first clinical site for the Phase I trial of HG-CT-1 is a milestone in our mission to revolutionize the treatment landscape for relapsed and refractory acute myeloid leukemia. This trial offers hope to patients who currently face limited treatment options by exploring the safety and potential efficacy of HG-CT-1. We are excited to start this pivotal study."

About AML and CAR-T Therapy

AML, the most common type of acute leukemia in adults, has poor survival rates (a five-year survival rate of less than 30% in adults) and is currently treated using chemotherapy, rather than the potentially more benign and effective forms of therapy being developed by Hemogenyx Pharmaceuticals. The successful development of a new therapy for AML would have a major impact on treatment and survival rates for the disease.

CAR-T therapy is a treatment in which a patient's own T-cells, a type of immune cell, are modified to recognize and kill the patient's cancer cells. The procedure involves: isolating T-cells from the patient; modifying the isolated T-cells in a laboratory using a CAR gene construct (which allows the cells to recognize the patient's cancer); amplifying (growing to large numbers) the newly modified cells; and re-introducing the cells back into the patient.

I hope you knew that it was SP Angel who was the lead on the failed placing.

I will eat my hat if they raise funding with no discount.

HEMO tried to raise £3m in early October 2024 at 1p when the stock was at 1.35p, but they could not get enough investor to put in £3m at that price so it failed. I think the main reason why that placing failed was because the company said that £3m would only take them to March 2025. Which is obvious a very poor proposition, raise money but need more money only within a few months.

Any investor in the upcoming placing will set the terms as the company is skint and investor are aware that the October £3m placing failed.

I guess its placing time now, £2 placing anyone?

Is it only me who think its odd that there is no update from KOD? Hainan update was clearly material, KOD should RNS something.

HEMOGENYX PHARMACEUTICALS (HEMO) Collaboration to develop ultrafast CAR-T manufacturing process for AML Treatment. +2%

If funding was in place they would announce it.